About Us

Our eyes are a tool for much more than vision. We use them to connect and communicate with the people and the world around us. Cloudbreak Pharma is on a mission to ensure no one is held back by poor eye health. We aim to help people prosper by treating a variety of eye conditions that compromise vision and quality of life. 

We are a clinical-stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that are amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 – an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy.

Management

Jinsong Ni, PhD Cloudbreak Therapeutics Founder and CEO

Jinsong Ni, Ph.D

Founder, Chief Executive Officer

Rebecca Chan, CPA, MBA, LLB

Director, Chief Financial Officer

Abu Abraham

Abu Abraham, MD

Chief Medical Officer

Van Dinh MBA Cloudbreak Therapeutics Co-Founder and COO

Van Dinh, MBA

Chief Operating Officer

我的專案 (1)

Rong Yang, Ph.D

Chief Scientific Officer

我的專案

Greg Brooks, B.Sc

Chief Commercial Officer

WenKui Fang

W. Ken Fang, Ph.D

Chief Innovation Officer

Elizabeth Capan

Elizabeth Capan, J.D.

Chief Patent Officer

Scientific Advisory Board

Our Partners


Santen Pharmaceutical Co., Ltd.
(TYO:4536)

In August 2024, Cloudbreak and Santen entered into a licensing agreement for CBT-001, Cloudbreak’s investigational proprietary multi-kinase inhibitor for the treatment of pterygium in, to develop, manufacture and commercialize the drug products in Japan, South Korea, Vietnam, Thailand, Malaysia, Philippines, Singapore, and Indonesia.

Grand Pharma
(00512.HK)

In April 2020, Cloudbreak and Grand Pharma entered into a commercialisation licensing arrangement which Grand Pharma is granted with an exclusive, sublicensable, royalty-bearing license to manufacture and commercialise CBT-001 in mainland China, Hong Kong, Macau and Taiwan region.